Figure 1.
Pharmacokinetic simulations of t‐PA levels over time relative to its native inhibitor (PAI‐1) in patients with COVID‐19 based on various body mass and bolus/maintenance doses of t‐PA. The model assumes a plasma clearance of 8.3 min, and a terminal half‐life of 88 min. 82 PAI‐1, plasminogen activator inhibitor‐1; t‐PA, tissue‐type plasminogen activator